— Weight Loss · Reference
What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
What ending treatment actually does, category by category: which effects fade, which reverse, where regain is the expected outcome, and how to stop in a way that keeps what you gained.
— Treatments mentioned
What happens when you stop depends entirely on the category: GLP-1 appetite suppression ends and regain is common without a maintenance plan, growth-hormone-axis effects fade over weeks as your own pulse returns to its baseline, repair peptides are simply finished when the episode is finished, and skin effects fade gradually as turnover continues without the input. None of these peptides produce a physical dependence or a withdrawal syndrome in the way that word is usually meant. The one category that genuinely needs a plan rather than a decision is the GLP-1s, and the commonest avoidable outcome in this whole field is someone quietly cancelling a GLP-1 subscription and regaining the weight.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
The short answer
| What you were taking | What happens when you stop | How quickly | Does it need a plan? |
|---|---|---|---|
| Semaglutide, tirzepatide | Appetite and gastric emptying return to baseline; regain is common | Appetite within weeks of the last dose | Yes, and the plan should exist before you stop |
| Sermorelin, CJC-1295 / Ipamorelin | Your own GH pulse returns to its untreated baseline; sleep and recovery effects fade | Over weeks | Usually no taper, but tell your physician |
| ASCEND, TITAN | Same as above, across the GH-axis components | Over weeks | Same |
| BPC-157 + TB-500, KLOW | Nothing to withdraw from; the course was for an episode | Not applicable | No, but a returning complaint warrants reassessment |
| GHK-Cu, RADIANCE | Skin continues its own turnover without the input; changes fade | Over months | No |
| Semax, Selank | Effects are not cumulative in the way GH-axis effects are; they end | Days | No |
| PT-141 | Acts per dose, so stopping simply means no further doses | Immediate | No |
| NAD+, MOTS-c | Any perceived effect fades | Weeks | No |
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
What decides how stopping feels
Three properties decide almost everything below. Half-life: a peptide cleared in minutes has nothing to fade from, while one engineered to bind albumin and survive a week is still working after you stop. Whether the effect was per-dose, or changed a state — body weight, visceral fat, an IGF-1 level — that persists and then drifts. And whether your own physiology was doing the work: sermorelin, ipamorelin, CJC-1295 and tesamorelin prompt your own pituitary, so nothing was bypassed and nothing has to be recovered. Behind all three sits whether the underlying problem resolves — a torn muscle recovers and stays recovered; obesity, in the framing the trials themselves use, does not.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
GLP-1 medications: the category that needs a plan
This is the one worth reading carefully, because it is where people lose what they paid for.
The mechanism explains the outcome. A GLP-1 receptor agonist prompts insulin release when glucose is high, suppresses glucagon, slows gastric emptying and acts on appetite centres in the brain. Remove it and all four revert. Appetite returns, meals feel smaller for less long, and the calorie deficit that produced the loss disappears unless something replaced it. Studies of the branded products report that most people regain a substantial share of lost weight after discontinuation.
That is not an argument that treatment has to be permanent. It is an argument that stopping is a plan rather than a date.
— What the STEP 1 extension measured
STEP 1 randomized 1,961 adults with obesity, or overweight with a weight-related condition and without diabetes, to 68 weeks of once-weekly subcutaneous semaglutide 2.4 mg or placebo alongside a lifestyle intervention. At week 68 everything stopped — medication and lifestyle programme — and an off-treatment extension followed 327 participants for a further year.
The numbers, reported in Diabetes, Obesity and Metabolism in 2022: mean weight loss from week 0 to week 68 was 17.3% with semaglutide and 2.0% with placebo. In the year after withdrawal the semaglutide group regained 11.6 percentage points of that loss and the placebo group 1.9, leaving net losses at week 120 of 5.6% and 0.1%. The authors' summary is that participants regained about two-thirds of their prior weight loss, with cardiometabolic improvements reverting toward baseline for most variables.
Regain was not total — a net 5.6% was still held a year after the last injection. But blood pressure, lipids and glycaemic markers moved with the weight rather than staying behind, which is the part people rarely plan for.
— What SURMOUNT-4 showed for tirzepatide
SURMOUNT-4, published in JAMA in 2024, was built as a randomized withdrawal trial — the cleanest way to ask this question. Participants took open-label tirzepatide at their maximum tolerated dose for 36 weeks and lost a mean of 20.9%. Then 670 were randomized to continue tirzepatide or switch to placebo for 52 weeks. From week 36 to week 88 the continued-tirzepatide group changed by -5.5% and the placebo group by +14.0%, a difference of 19.4 percentage points; 89.5% of those who continued still held at least 80% of their lead-in weight loss, against 16.6% of those switched to placebo. The placebo group did not know they had stopped, and regained anyway.
— STEP 4, and why "continue or switch" is the real question
STEP 4, published in JAMA in 2021, ran a 20-week semaglutide run-in and then randomized 803 people who had reached the 2.4 mg maintenance dose to continue or switch to placebo for 48 weeks. Continued semaglutide produced a further -7.9%; the placebo switch produced +6.9%. The comparison was not treatment versus nothing but continuing versus stopping, with the lifestyle programme running in both arms. Between them these three trials say the same thing from three directions, in more than 1,700 randomized participants.
— How long semaglutide and tirzepatide actually stay in you
The approved labels are specific. The Wegovy label puts semaglutide's elimination half-life at approximately one week, and states that semaglutide will be present in the circulation for about five to seven weeks after the last injectable dose. The Zepbound label gives tirzepatide an elimination half-life of approximately five to six days in patients with overweight or obesity. Those are the reference-listed branded products; compounded semaglutide and compounded tirzepatide contain the same active molecules, so the same pharmacokinetics apply, but a compounded preparation is not FDA approved and carries no label of its own.
So nothing happens on day one. The first missed weekly dose sits inside the half-life of the dose before it, so the concentration slides rather than drops, and most people describe appetite returning over the second to fourth week after the last injection, with gastric emptying speeding up over the same window. A stop is invisible for long enough to feel like it worked, and then is not. Judge it at eight weeks, not at ten days.
Stopping approach What it involves When it is considered Maintenance dose Staying on a lower dose long term When appetite regulation is the thing being treated Structured step down Reducing gradually while habits carry more of the load When someone wants off but not abruptly Stop with the scaffolding in place first Protein intake, resistance training and a weighing routine established before the last dose Any planned stop Abrupt stop, no plan Nothing This is the one associated with regain Two practical notes. Stopping shortly after a dose increase can be uncomfortable, and running out because a refill lapsed is not the same as a decision. If cost is the reason, say so to your prescriber: a lower dose or a different medication is a conversation, and it is a better outcome than silently cancelling.
— A lapsed refill is not a decision
Every vial is sized around a 28-day fill, and treatment runs continuously across those fills. A shipment four days late is nothing; a fill that never gets placed becomes an unplanned stop that nobody recorded. If cost is the reason, the published all-in figures for semaglutide and tirzepatide are the start of that conversation, not the end of it.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Growth-hormone axis: fade, not crash
Sermorelin, ipamorelin, CJC-1295 and tesamorelin work by prompting your own pituitary to release growth hormone in a pulse. Because your pituitary does the releasing, the feedback machinery stays in place, including somatostatin and IGF-1 signalling. That is the structural reason this category does not behave like supplied hormone.
| Question | Answer |
|---|---|
| Is there suppression to recover from? | Not in the way there is with exogenous hormone, because your own axis was doing the work |
| Do I need a taper? | Usually not, though your physician may have a view for your case |
| What fades, and how fast? | The sleep and recovery effects patients report, over weeks rather than overnight |
| What happens to IGF-1? | It returns toward your untreated baseline, which is why a follow-up lab after stopping is informative |
| Will I lose the training gains? | Muscle and strength respond to training and protein. Stopping the peptide does not delete work you did, though recovery capacity may feel different |
— The one human study that measured responsiveness after stopping
Most of what is written about this category is mechanistic argument. There is one directly relevant human measurement. A 1998 study in the Journal of Clinical Endocrinology and Metabolism gave adults twice-daily subcutaneous hexarelin for 16 weeks and measured the GH response to a test dose at intervals. That response was attenuated at weeks 4 and 16 compared with baseline; four weeks after treatment ended it had risen again and was not significantly different from where it started, while IGF-1 and IGF binding protein-3 did not change significantly across the 20 weeks.
Hexarelin is a different molecule from ipamorelin, and one small study is not a general law. But it measured the thing people worry about — that a secretagogue leaves the pituitary blunted — and reported reversible attenuation that recovered within a month of stopping.
— Tesamorelin and visceral fat: the documented exception
One GH-axis result is documented to reverse, and it is fair to say so plainly. In the phase 3 programme for tesamorelin in patients with HIV and excess abdominal fat, published in the Journal of Acquired Immune Deficiency Syndromes in 2010, participants were re-randomized at six months to continue tesamorelin or switch to placebo. Those who continued held a visceral adipose tissue reduction of roughly 18% at twelve months. In the authors' own words, the initial improvements in visceral fat "were rapidly lost" in those who switched to placebo.
That is a finding in a specific population and indication, not a statement about body composition in general — but it is the clearest available answer to whether visceral fat returns after a GH-axis peptide stops. Tesamorelin is the active component in TITAN, PHYSIQ and the tesamorelin + ipamorelin pair.
— IGF-1, sleep and what is worth measuring afterwards
IGF-1 is the one number in this category that moves and can be measured. CJC-1295 was reported in the Journal of Clinical Endocrinology and Metabolism in 2006 to raise GH and IGF-1 in healthy adults for a prolonged period after dosing, with a companion paper reporting that GH secretion stayed pulsatile. When the stimulation stops, the level drifts back toward where your untreated axis holds it, so a lab a few weeks after the last dose tells you your own baseline. At-home blood testing covers IGF-1 alongside hormone and metabolic markers without a lab visit.
The effects people report most from sermorelin and CJC-1295 / Ipamorelin — deeper sleep, easier recovery — have no trial endpoint attached and therefore no measured fade curve. What prescribers describe is a return to the prior pattern over a few weeks, with no rebound below baseline.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Repair peptides: the course ends because the episode ended
BPC-157, TB-500, KPV and the repair blends are prescribed for a defined problem. When the problem resolves, the prescription has done what it was for. There is nothing to withdraw from and no rebound described.
What matters instead is the question of why the complaint arose. A tendon that settled while you were also rehabilitating and then flares the moment you return to the load that caused it has not been treated, it has been rested. If the complaint returns, that is a reason to be reassessed rather than to restart alone, and it is frequently a reason to look at the loading programme rather than the vial.
Why there is no discontinuation literature here
The published research on BPC-157 is animal and cell work — angiogenesis through VEGFR2, growth hormone receptor expression in cultured tendon fibroblasts reported in Molecules in 2014, tendon reattachment in rats in the Journal of Orthopaedic Research in 2006. There are no large randomised controlled trials of BPC-157 in humans, and therefore no randomized withdrawal study either; the same holds for TB-500. So the honest statement is not that stopping BPC-157 is safe because a trial showed it — it is that no withdrawal phenomenon has been described for these molecules anywhere in the literature.
KPV, the inflammation blends, and a complaint that returns
KPV is a tripeptide fragment of alpha-MSH, described in Gastroenterology in 2008 as reducing intestinal inflammation in animal and cell models. If a systemic inflammatory picture was the reason for treatment, it can return when treatment ends — not as rebound, but because the driver was never removed. A problem returning on the same footing as before is a different conversation from one returning worse, and both belong with the physician.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Skin, hair and collagen: months, not overnight
GHK-Cu and the turnover argument
GHK-Cu is a copper-binding tripeptide described since a 1988 paper in FEBS Letters as stimulating collagen synthesis in cultured fibroblasts, with later gene-expression and wound-model work reviewed in the International Journal of Molecular Sciences in 2018. Skin does not hold a state; it replaces itself continuously. When the input stops, tissue produced during treatment stays until it turns over in the ordinary way, which is why changes fade over months rather than reversing — and the fade only shows up in comparison, so photographs at fixed intervals under the same light are the only reliable way to see it. The same applies to the GHK-Cu blends: RADIANCE, ETERNAL, REVIVE and GLOW.
Melanotan II is the visible exception
Melanotan II is the one compound here where stopping produces an obvious, predictable change: pigmentation induced by a melanocortin agonist fades as the pigmented cells turn over, on the timescale of any tan. Human work with melanocortin analogues, including the 1996 pilot study in Life Sciences, describes pigmentation as dose-dependent and reversible. Existing moles and any skin history belong in the conversation with your physician before starting.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Cognitive, mood and sleep peptides: nothing accumulates
Semax and Selank
Semax and Selank are short peptides with rapid clearance. The Russian clinical literature on Selank, including a comparison with a benzodiazepine in Zh Nevrol Psikhiatr in 2014, is notable for reporting an anxiolytic effect without the dependence and discontinuation profile that class carries. Semax has been described in Brain Research in 2006 as regulating BDNF and trkB expression in rat hippocampus. When these stop, they stop: the effect is per-dose, the molecule clears quickly, and no rebound anxiety has been described. The nasal formats and the Semax + Selank pair behave the same way.
DSIP and sleep
DSIP has a small and old human literature — controlled studies in chronic insomnia in the 1980s, in journals including European Neurology and Neuropsychobiology, with mixed results. What is not described anywhere in it is rebound insomnia on stopping, the characteristic problem with sedative-hypnotics and the reason the question gets asked. If sleep returns to its prior pattern, that pattern is the thing to take back to the physician.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Intimacy peptides: dose-by-dose by design
PT-141, oxytocin and kisspeptin
PT-141 is bremelanotide, a melanocortin receptor agonist taken before intimacy rather than daily; its development programme, including the long-term safety and efficacy data published in Obstetrics & Gynecology in 2019, studied it as an as-needed medication. There is no accumulated state to lose, so stopping means no further doses and nothing else. Oxytocin behaves the same way, and the PT-141 + Oxytocin preparation exists because those two are frequently used together.
Kisspeptin is the one compound here where the research describes something specific about repeated use: a 2009 study in the Journal of Clinical Endocrinology and Metabolism reported that twice-daily kisspeptin-54 over two weeks produced tachyphylaxis, the gonadotropin response markedly reduced by day 14 while the pituitary remained fully responsive to GnRH. That concerns continuing rather than stopping, and the preserved responsiveness is the reassuring part.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Metabolic, cellular and immune peptides
NAD+ raises a cofactor your cells consume continuously; when supplementation stops, levels return to what your own synthesis sustains, and the randomized human work here — nicotinamide riboside in Nature Communications in 2018, nicotinamide mononucleotide in Science in 2021 — describes no withdrawal phenomenon. MOTS-c is a mitochondrial-derived peptide described in Cell Metabolism in 2015 as a regulator of metabolic homeostasis in mice. SS-31 has the most substantial human trial record, as elamipretide in primary mitochondrial myopathy, and Thymosin Alpha-1 has randomized evidence in chronic hepatitis B and in sepsis, including a phase 3 trial in the BMJ in 2025. In none of these four is a below-baseline overshoot described: any perceived effect fades over weeks, and where treatment was prescribed for an ongoing clinical reason, that reason determines how long it runs.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
What "withdrawal" actually means, and why none of this is that
The word carries three meanings, and conflating them is what makes people anxious about stopping.
| Meaning | What it is | Does it apply here |
|---|---|---|
| Physical dependence | A physiological state in which abrupt cessation produces a characteristic syndrome, as with alcohol, benzodiazepines and opioids | No peptide in this catalogue has been described as producing this |
| Rebound below baseline | An overshoot where the symptom returns worse than before treatment | Not described for any of these compounds |
| Simple loss of effect | The drug clears, the mechanism stops, and your physiology does what it did before | Yes — this is what actually happens |
For semaglutide and tirzepatide that third line is consequential, because the physiology it returns to is the one that produced the weight in the first place. For a repair peptide it is usually of no consequence, because the tissue question was settled while treatment ran.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Where these medications stand with the FDA right now
Semaglutide and tirzepatide are FDA approved as branded products, and the label facts above come from those approvals. A compounded preparation containing the same active ingredient is not FDA approved as a finished drug product — compounded medications are prepared by a licensed pharmacy pursuant to a prescription rather than approved as manufactured products.
For the compounded peptides, the FDA's interim policy sorts nominated bulk drug substances into three categories, Category 2 being those where the agency has identified significant safety risks; the same guidance states that the agency does not intend to place substances nominated on or after 7 January 2025 into these categories at all. The FDA's Category 2 page, current as of 22 April 2026, now carries a second table headed "Bulk drug substances nominated but withdrawn"; BPC-157, TB-500, GHK-Cu for injectable routes, KPV, MOTS-c, Semax, Selank, DSIP, thymosin alpha-1 and CJC-1295 appear there rather than in the Category 2 table itself. The Pharmacy Compounding Advisory Committee met on 23–24 July 2026 to consider nominations for the 503A bulks list.
None of that changes anything about stopping. It matters only because people occasionally stop a medication after reading an out-of-date summary of its regulatory status, which is the worst reason on this page. What Pepti publishes about sourcing and testing is on quality and lab results.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
If you are stopping for a reason, say which
| Reason you want to stop | What a prescriber can usually do | What happens if you do not say |
|---|---|---|
| Cost | Discuss a lower dose, a different medication, or pausing deliberately | You cancel, and on a GLP-1 you regain |
| Side effects | Adjust dose, change timing, or switch | A tolerable problem ends treatment that was working |
| It is not working | Check dose, check labs, reconsider the diagnosis | You conclude a whole category failed when one variable was wrong |
| You reached your goal | Plan maintenance, or plan the stop properly | The commonest regain story there is |
| You are pregnant or trying to conceive | Stop appropriately, which is the right answer here | See can you take peptides while pregnant |
| Surgery or a new diagnosis | Coordinate with the treating team | Your surgeon does not know what you are taking |
None of these conversations take long, and all of them are better than a cancelled subscription and a silence.
Surgery, pregnancy and a changing medication list
A GLP-1 medication slows gastric emptying, which is directly relevant to anesthesia planning, and the long half-life means the effect persists well past the last dose. Your surgeon and anesthetist need to know what you take and when the last injection was — not so they can refuse, but so they can plan.
The Wegovy label instructs discontinuation at least two months before a planned pregnancy because of semaglutide's long half-life. That is the clearest example of why stopping timing is a medical question rather than a personal one; the broader picture is in can you take peptides while pregnant.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
Monitoring around a stop
There is no universal panel for stopping, and your physician decides what applies. A lab is genuinely informative in two situations: a GH-axis medication, where an IGF-1 drawn a few weeks after the last dose shows your own baseline, and a GLP-1, where the metabolic markers that improved during treatment are the ones the STEP 1 extension reported drifting back.
Without a lab, track weight on a fixed schedule, because regain is gradual and a weekly number catches it while it is still a conversation; photographs at fixed intervals for anything skin-related; and whether a symptom returned on the same footing it left on. How do I know if peptides are working covers measurement properly.
— What Happens When You Stop Taking Peptides? Rebound, Fade and Planning
What the evidence shows, honestly
The discontinuation data is strong in exactly one place. For the branded GLP-1 medications, randomised withdrawal studies document substantial weight regain after stopping for most participants. Compounded preparations share the active ingredient but not the approval, and no discontinuation trial has been run on a compounded preparation, so the mechanism is the basis for expecting the same pattern.
For the growth-hormone secretagogues, the absence of a crash on stopping is a mechanistic argument rather than a trial finding: the pituitary was doing the releasing and the feedback loops were intact throughout. It is a sound argument and it is not the same as a study.
For BPC-157, TB-500, KPV, GHK-Cu and the rest, there is essentially no published discontinuation literature at all, because the published research is preclinical to begin with. What can be said is that no withdrawal syndrome has been described for these molecules, and that they are prescribed as courses rather than as indefinite treatment.
Compounded medications are not FDA approved. Response varies between people, on the way in and on the way out.
What the evidence does not establish
- It does not establish that regain is inevitable for any individual. The STEP 1 extension reported a net 5.6% loss still held a year after the last dose.
- It does not establish a fade curve for any of the preclinical peptides, because nobody has measured one.
- It does not establish that a compounded preparation behaves identically to the branded product on withdrawal. The molecule is the same; no trial has tested the compounded version.
- It does not establish a right length of treatment for anyone. That is a clinical judgement.
— References
What this is based on.
References
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules (2014) · PMID 25415472
- Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment of rat and stable gastric pentadecapeptide BPC 157 · Journal of Orthopaedic Research (2006) · PMID 16583442
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design (2011) · PMID 21548867
- Cerovecki T, Bojanic I, Brcic L, Radic B, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res (2010) · PMID 20225319
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation · Curr Pharm Des (2014) · PMID 23755725
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H · Drug Test Anal (2017) · PMID 28035768
- Thomas A, Görgens C, Guddat S et al.. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry · J Sep Sci (2016) · PMID 26578461
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL et al.. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale · Pain (2001) · PMID 11690728
- Meyer JD, Ho B, Manning MC. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides · Pharm Biotechnol (2002) · PMID 11987755
- Xu C, Sun L, Ren F, Huang P, et al.. Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds · Regul Toxicol Pharmacol (2020) · PMID 32334036
- He L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs · Front Pharmacol (2022) · PMID 36588717
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain · Altern Ther Health Med (2021) · PMID 34324435
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
— Common questions
What Happens When You Stop Taking Peptides? Rebound, Fade and Planning, answered.
Regain is common without a plan, because the appetite suppression the loss depended on goes away. In the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, participants regained about two-thirds of their prior weight loss in the year after semaglutide and the lifestyle programme were both withdrawn. In SURMOUNT-4 (JAMA, 2024), people switched from tirzepatide to placebo gained 14.0% over 52 weeks while those who continued lost a further 5.5%. Whether that happens to you depends largely on whether protein, training and a weighing routine were in place before the last dose.
No withdrawal syndrome has been described for the peptides in this catalogue. What happens is that effects fade as the drug clears and your own physiology returns to its baseline. That is different from withdrawal, and confusing the two causes unnecessary alarm.
Usually not. These prompt your own pituitary rather than supplying hormone, so the feedback system was never bypassed. Tell your physician you are stopping anyway, because a follow-up IGF-1 is informative. The closest human measurement is a 1998 study in the Journal of Clinical Endocrinology and Metabolism, in which the GH response to a secretagogue was attenuated over 16 weeks of treatment and had returned to baseline four weeks after it ended.
Repair peptides are prescribed for an episode, and when the episode ends the course ends. If the complaint returns, the usual reason is the load or movement that caused it, not the absence of the peptide. That is a reassessment, not a refill.
Skin continues turning over without the input, so changes fade gradually over months rather than reversing overnight. Photographs at fixed intervals are the only reliable way to see it either direction: see how do I know if peptides are working.
Often yes, and it is far better done deliberately than by letting a refill lapse. Tell your care team so the pause is recorded and the restart reviewed, especially on a GLP-1 where restarting may mean stepping the dose again rather than resuming where you left off.
It depends on the category and on the reason. Cycling is sometimes about tolerance, sometimes about cost, and sometimes about nothing at all. The honest version of that argument is in peptide cycling and tolerance.
The Wegovy label puts semaglutide's elimination half-life at approximately one week and states it will be present in the circulation for about five to seven weeks after the last injectable dose. Compounded semaglutide contains the same molecule, though it is not FDA approved as a finished product.
The Zepbound label gives an elimination half-life of approximately five to six days in patients with overweight or obesity. That is why appetite typically returns over the second to fourth week after the last injection rather than immediately.
Treat it as an unplanned stop and say so. Vials are sized around a 28-day fill and treatment runs continuously across them, so a gap is a supply problem with a clinical consequence — particularly on a GLP-1, where restarting after a long gap may mean stepping the dose again. Contact your care team rather than waiting to see what happens.
Nothing in the published work describes that. These peptides prompt your own pituitary rather than supplying hormone, and the one human study to measure responsiveness after stopping reported it returning to baseline within four weeks. Your physician may still want an IGF-1 afterwards, which is the only way to know your own number rather than assume it.
In the phase 3 programme reported in the Journal of Acquired Immune Deficiency Syndromes in 2010, participants with HIV and excess abdominal fat who switched from tesamorelin to placebo at six months rapidly lost the visceral fat reduction they had gained, while those who continued held roughly an 18% reduction at twelve months — the clearest documented example in this category of an effect that reverses rather than fades.
No. Both are used per dose rather than accumulated, and both clear quickly, so stopping means no further doses and nothing else. Kisspeptin is the one compound in this group where the research describes a response diminishing with repeated dosing, and there the pituitary remained fully responsive to its natural signal throughout. You can also stop one peptide and keep taking another — tell your prescriber which one and why, because the answer for one category says nothing about the other. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Yes, and it is common — someone finishing a repair prescription while continuing something on the GH axis. Tell your prescriber which one you are stopping and why, because the answer for one category says nothing about the other. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
— Next step
See what a physician
recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.
Important legal & safety information
The assessment process available on the Pepti website asks a series of medical questions, and the answers provided are reviewed by an independent licensed physician affiliated with our partner physician network. The licensed providers have established exclusionary criteria, and the answers provided determine if the individual is screened out of eligibility for treatment. The licensed clinicians retain the sole decision to prescribe peptide therapy and other compounded medications to patients. Treatment may be denied at the physician's sole discretion. If a prescription is not approved, you will not be charged for the medication.
Pharmacy Providers. Pepti is a technology platform and is not a healthcare provider, pharmacy, or prescriber. All medications offered through the platform are compounded by independent FDA-registered 503A or 503B compounding pharmacies based on a valid prescription written by a licensed physician for an individual patient. Compounded medications are not FDA-approved as products. The active pharmaceutical ingredients used by our partner pharmacies are sourced from FDA-registered facilities. Compounded medications may not undergo the same testing or quality control as commercially manufactured FDA-approved drugs.
Results vary. Results from peptide therapy and other compounded treatments vary based on individual factors, including age, weight, medical history, adherence to the prescribed protocol, lifestyle factors, and physiological response. Pepti makes no guarantee of any specific outcome. Statements about peptide therapy and compounded medications offered through the platform have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Product images. Product photographs and renderings shown on this website are for illustrative purposes only. The appearance of vials, packaging, labeling, and other materials you receive may vary and is determined by the dispensing compounding pharmacy.
Off-label use.Many peptides offered through the platform are prescribed for off-label use. “Off-label” means the medication is being prescribed for a use, dose, or patient population that is not specifically approved by the FDA. Off-label prescribing is legal and common in U.S. medical practice when supported by clinical experience and judgment.
Mailing & shipping. Pepti currently dispenses prescription medication to patients in all 50 states and Washington, D.C.. All orders ship in unbranded, tamper-evident packaging via expedited delivery from our partner compounding pharmacies. Temperature-sensitive medications ship with insulated packaging and ice packs. Shipping is included at no additional cost. We do not currently ship medication outside all 50 states and Washington, D.C., internationally, or to APO/FPO addresses.
Not for emergencies. Pepti is not designed for medical emergencies. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room immediately. For urgent but non-emergency medical questions, contact your primary care provider or use an urgent care service.
No doctor-patient relationship with Pepti. Your use of the platform does not create a doctor-patient relationship between you and pepti LLC. A doctor-patient relationship is established only between you and the independent licensed physician who reviews your intake and prescribes your treatment. The physicians who use the platform are independent contractors and are solely responsible for the medical care they provide.
Prescription medications. All prescription products require a valid prescription from a licensed healthcare provider. By using the platform, you acknowledge that you are at least 18 years old and that the information you provide is true, accurate, current, and complete. Providing false information may result in inappropriate treatment recommendations or denial of service.
Cosmetic & wellness products.Certain products offered through Pepti — including skincare, hair care, body care, supplements, men's grooming, sports recovery, and sexual wellness products — are cosmetic or dietary supplement products, not prescription medications. These products do not require a prescription and are not reviewed or prescribed by a physician. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Results vary by individual. Consult your healthcare provider before starting any new supplement or topical product, especially if you are pregnant, nursing, or taking other medications.
pepti LLC · Delaware Limited Liability Company · 131 Continental Dr, Suite 305, Newark, DE 19713 · For media or partnership inquiries, email hello@hellopepti.com. For patient support, email support@hellopepti.com. For privacy and HIPAA inquiries, email privacy@hellopepti.com.